{
    "studies": [
      {
        "protocolSection": {
          "identificationModule": {
            "nctId": "NCT00770510",
            "orgStudyIdInfo": {
              "id": "190-126"
            },
            "organization": {
              "fullName": "Eisai Inc.",
              "class": "INDUSTRY"
            },
            "briefTitle": "A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)",
            "officialTitle": "A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia"
          },
          "statusModule": {
            "statusVerifiedDate": "2012-12",
            "overallStatus": "COMPLETED",
            "expandedAccessInfo": {
              "hasExpandedAccess": false
            },
            "startDateStruct": {
              "date": "2008-09"
            },
            "primaryCompletionDateStruct": {
              "date": "2010-05",
              "type": "ACTUAL"
            },
            "completionDateStruct": {
              "date": "2010-05",
              "type": "ACTUAL"
            },
            "studyFirstSubmitDate": "2008-10-09",
            "studyFirstSubmitQcDate": "2008-10-09",
            "studyFirstPostDateStruct": {
              "date": "2008-10-10",
              "type": "ESTIMATED"
            },
            "resultsFirstSubmitDate": "2012-12-28",
            "resultsFirstSubmitQcDate": "2012-12-28",
            "resultsFirstPostDateStruct": {
              "date": "2013-02-04",
              "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2012-12-28",
            "lastUpdatePostDateStruct": {
              "date": "2013-02-04",
              "type": "ESTIMATED"
            }
          },
          "sponsorCollaboratorsModule": {
            "responsibleParty": {
              "type": "SPONSOR"
            },
            "leadSponsor": {
              "name": "Eisai Co., Ltd.",
              "class": "INDUSTRY"
            }
          },
          "oversightModule": {
            "oversightHasDmc": false
          },
          "descriptionModule": {
            "briefSummary": "The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.",
            "detailedDescription": "This is a multicenter, randomized, double-blind, placebo-controlled, 5-way cross-over study to investigate and evaluate the efficacy of eszopiclone in Japanese participants with primary insomnia. The treatment period consists of two consecutive days (two nights) as one term. Patients will receive oral eszopiclone (1, 2, 3 mg), zolpidem tartrate (10 mg), or placebo once daily at bedtime for each use. Participants were randomly assigned to one of 10 prespecified treatment sequence patterns."
          },
          "conditionsModule": {
            "conditions": [
              "Primary Insomnia"
            ],
            "keywords": [
              "Primary insomnia"
            ]
          },
          "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
              "PHASE2",
              "PHASE3"
            ],
            "designInfo": {
              "allocation": "RANDOMIZED",
              "interventionModel": "CROSSOVER",
              "primaryPurpose": "TREATMENT",
              "maskingInfo": {
                "masking": "DOUBLE",
                "whoMasked": [
                  "PARTICIPANT",
                  "INVESTIGATOR"
                ]
              }
            },
            "enrollmentInfo": {
              "count": 192,
              "type": "ACTUAL"
            }
          },
          "armsInterventionsModule": {
            "armGroups": [
              {
                "label": "Eszopiclone 1 mg",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 1 mg"
                ]
              },
              {
                "label": "Eszopiclone 2 mg",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 2 mg"
                ]
              },
              {
                "label": "Eszopiclone 3 mg",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 3 mg"
                ]
              },
              {
                "label": "Placebo",
                "type": "PLACEBO_COMPARATOR",
                "interventionNames": [
                  "Drug: Placebo"
                ]
              },
              {
                "label": "Zolpidem Tartrate 10 mg",
                "type": "ACTIVE_COMPARATOR",
                "interventionNames": [
                  "Drug: Zolpidem Tartrate 10 mg"
                ]
              }
            ],
            "interventions": [
              {
                "type": "DRUG",
                "name": "Eszopiclone 1 mg",
                "description": "Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.",
                "armGroupLabels": [
                  "Eszopiclone 1 mg"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              },
              {
                "type": "DRUG",
                "name": "Eszopiclone 2 mg",
                "description": "Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.",
                "armGroupLabels": [
                  "Eszopiclone 2 mg"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              },
              {
                "type": "DRUG",
                "name": "Eszopiclone 3 mg",
                "description": "Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.",
                "armGroupLabels": [
                  "Eszopiclone 3 mg"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              },
              {
                "type": "DRUG",
                "name": "Placebo",
                "description": "Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.",
                "armGroupLabels": [
                  "Placebo"
                ]
              },
              {
                "type": "DRUG",
                "name": "Zolpidem Tartrate 10 mg",
                "description": "Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.",
                "armGroupLabels": [
                  "Zolpidem Tartrate 10 mg"
                ]
              }
            ]
          },
          "outcomesModule": {
            "primaryOutcomes": [
              {
                "measure": "Latency To Persistent Sleep (LPS)",
                "description": "The objective measure, LPS, defined as the amount of time measured in minutes it takes to fall asleep was based on polysomnography (PSG) objective assessments of sleep disturbance. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.",
                "timeFrame": "10 days (5 intervals of two consecutive nights)"
              },
              {
                "measure": "Sleep Latency (SL)",
                "description": "The subjective measure, SL, defined as the amount of time measured in minutes it takes to fall asleep was based on participant-reported subjective assessments of sleep disturbance and was obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "timeFrame": "10 days (5 intervals of two consecutive nights)"
              }
            ],
            "secondaryOutcomes": [
              {
                "measure": "Total Sleep Time (Objective & Subjective)",
                "description": "Total sleep time defined as total sleeping time from bedtime to final awakening (measured in minutes) was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective total sleep time was based on PSG-based assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments of sleep disturbance and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "timeFrame": "10 days (5 intervals of two consecutive nights)"
              },
              {
                "measure": "Sleep Efficiency",
                "description": "Sleep efficiency (SE) was an assessment obtained from PSG during the treatment period and was defined as the ratio of total sleep time to the total time in bed of 8 hours \\* 100, expressed as a percent.\n\nPSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the patient's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.",
                "timeFrame": "10 days (5 intervals of two consecutive nights)"
              },
              {
                "measure": "Wake Time After Sleep Onset (WASO)- Objective & Subjective",
                "description": "Wake Time After Sleep Onset (WASO) defined as total awakening time from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective WASO was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "timeFrame": "10 days (5 intervals of two consecutive nights)"
              },
              {
                "measure": "Number of Awakenings (Objective & Subjective)",
                "description": "Number of awakenings defined as the total number of spontaneous awakenings from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective number of awakenings was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "timeFrame": "10 days (5 intervals of two consecutive nights)"
              }
            ]
          },
          "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Participants aged greater than or equal to 21 and less than 65 years at the time of obtaining written informed consent\n2. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version and have both of the following conditions which are persistent for more than or equal to 4 weeks before the start of observation period:\n\n   * Sleep latency of more than or equal to 30 minutes for more than or equal to 3 days a week\n   * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week\n3. Participants who meet both of the following based on polysomnogram (PSG) in observation period:\n\n   * Objective sleep latency of more than or equal to 20 minutes for 2 consecutive PSG days\n   * Objective total sleep time of less than or equal to 420 minutes for 2 consecutive PSG days, or objective wake time during sleep of more than or equal to 20 minutes for 2 consecutive PSG days\n\nExclusion Criteria:\n\n1. Participants with comorbid primary sleep disorders (e.g., circadian rhythm disorder, restless limb syndrome, periodic limb movement disorder, sleep apnea syndrome), other than primary insomnia.\n2. Participants with insomnia caused by pharmacological actions (drug-induced insomnia).\n3. Participants with comorbid sleep disorder associated with other disease(s) such as psychiatric and/or physical disease(s).\n4. Participants with a complication of psychiatric disorders in Axis I or personality disorder in Axis II defined in DSM-IV-TR Japanese version.\n5. Participants with organic mental disorder.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "64 Years",
            "stdAges": [
              "ADULT"
            ]
          },
          "contactsLocationsModule": {
            "overallOfficials": [
              {
                "name": "Atsushi Kamijo",
                "affiliation": "New Product Development Department, Clinical Research Center",
                "role": "STUDY_DIRECTOR"
              }
            ],
            "locations": [
              {
                "city": "Toyohashi",
                "state": "Aichi",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.76667,
                  "lon": 137.38333
                }
              },
              {
                "city": "Kitakyushu",
                "state": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.85181,
                  "lon": 130.85034
                }
              },
              {
                "city": "Kurume",
                "state": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.31667,
                  "lon": 130.51667
                }
              },
              {
                "city": "Otaru",
                "state": "Hokkaido",
                "country": "Japan",
                "geoPoint": {
                  "lat": 43.18944,
                  "lon": 141.00222
                }
              },
              {
                "city": "Sapporo",
                "state": "Hokkaido",
                "country": "Japan",
                "geoPoint": {
                  "lat": 43.06667,
                  "lon": 141.35
                }
              },
              {
                "city": "Kawasaki",
                "state": "Kanagawa",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.52056,
                  "lon": 139.71722
                }
              },
              {
                "city": "Urazoe",
                "state": "Okinawa",
                "country": "Japan",
                "geoPoint": {
                  "lat": 26.25444,
                  "lon": 127.70639
                }
              },
              {
                "city": "Sakai",
                "state": "Osaka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.58333,
                  "lon": 135.46667
                }
              },
              {
                "city": "Kodaira",
                "state": "Tokyo",
                "country": "Japan"
              },
              {
                "city": "Setagaya",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.64825,
                  "lon": 139.65376
                }
              },
              {
                "city": "Shibuya",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.469,
                  "lon": 140.29807
                }
              },
              {
                "city": "Akita",
                "country": "Japan",
                "geoPoint": {
                  "lat": 39.71667,
                  "lon": 140.10826
                }
              },
              {
                "city": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.6,
                  "lon": 130.41667
                }
              },
              {
                "city": "Gifu",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.42291,
                  "lon": 136.76039
                }
              },
              {
                "city": "Hiroshima",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.4,
                  "lon": 132.45
                }
              },
              {
                "city": "Kagoshima",
                "country": "Japan",
                "geoPoint": {
                  "lat": 31.56667,
                  "lon": 130.55
                }
              },
              {
                "city": "Kochi",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.55,
                  "lon": 133.53333
                }
              },
              {
                "city": "Kumamoto",
                "country": "Japan",
                "geoPoint": {
                  "lat": 32.80589,
                  "lon": 130.69182
                }
              },
              {
                "city": "Kyoto",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.02107,
                  "lon": 135.75385
                }
              },
              {
                "city": "Osaka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.69374,
                  "lon": 135.50218
                }
              }
            ]
          },
          "referencesModule": {
            "references": [
              {
                "pmid": "23063301",
                "type": "DERIVED",
                "citation": "Uchimura N, Kamijo A, Kuwahara H, Uchiyama M, Shimizu T, Chiba S, Inoue Y. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Med. 2012 Dec;13(10):1247-53. doi: 10.1016/j.sleep.2012.08.015. Epub 2012 Oct 11."
              }
            ]
          }
        },
        "resultsSection": {
          "participantFlowModule": {
            "preAssignmentDetails": "Of the 192 participants who entered the screening period, 72 were randomized to study medication (excluding 119 ineligible participants; one withdrawal of consent).",
            "recruitmentDetails": "This study was recruited at 21 centers in Japan.",
            "groups": [
              {
                "id": "FG000",
                "title": "Entire Study Population",
                "description": "Includes groups randomized to receive one of 10 prespecified treatment sequence patterns which included receiving: Eszopiclone 1 mg first, Eszopiclone 2 mg first, Eszopiclone 3 mg first, Placebo first, and Zolpidem Tartrate 10 mg first.\n\nGroup 1: ABECD (n=7) Group 2: BCADE (n=7) Group 3: CDBEA (n=7) Group 4: DECAB (n=8) Group 5: EADBC (n=7) Group 6: DCEBA (n=8) Group 7: EDACB (n=7) Group 8: AEBDC (n=7) Group 9: BACED (n=7) Group 10: CBDAE (n=7)\n\nA= Eszopiclone 3 mg; B= Eszopiclone 2 mg; C= Eszopiclone 1mg; D= Placebo; E: Zolpidem 10 mg"
              }
            ],
            "periods": [
              {
                "title": "Overall Study",
                "milestones": [
                  {
                    "type": "STARTED",
                    "achievements": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "72"
                      }
                    ]
                  },
                  {
                    "type": "COMPLETED",
                    "achievements": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "67"
                      }
                    ]
                  },
                  {
                    "type": "NOT COMPLETED",
                    "achievements": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "5"
                      }
                    ]
                  }
                ],
                "dropWithdraws": [
                  {
                    "type": "Lost to Follow-up",
                    "reasons": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "2"
                      }
                    ]
                  },
                  {
                    "type": "Pregnancy",
                    "reasons": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "1"
                      }
                    ]
                  },
                  {
                    "type": "Withdrawal by Subject",
                    "reasons": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "baselineCharacteristicsModule": {
            "groups": [
              {
                "id": "BG000",
                "title": "Entire Study Population",
                "description": "Includes groups randomized to receive one of 10 prespecified treatment sequence patterns which included receiving: Eszopiclone 1 mg first, Eszopiclone 2 mg first, Eszopiclone 3 mg first, Placebo first, and Zolpidem Tartrate 10 mg first.\n\nGroup 1: ABECD (n=7) Group 2: BCADE (n=7) Group 3: CDBEA (n=7) Group 4: DECAB (n=8) Group 5: EADBC (n=7) Group 6: DCEBA (n=8) Group 7: EDACB (n=7) Group 8: AEBDC (n=7) Group 9: BACED (n=7) Group 10: CBDAE (n=7)\n\nA= Eszopiclone 3 mg; B= Eszopiclone 2 mg; C= Eszopiclone 1mg; D= Placebo; E: Zolpidem 10 mg"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "BG000",
                    "value": "72"
                  }
                ]
              }
            ],
            "measures": [
              {
                "title": "Age Continuous",
                "paramType": "MEAN",
                "dispersionType": "STANDARD_DEVIATION",
                "unitOfMeasure": "years",
                "classes": [
                  {
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "BG000",
                            "value": "39.4",
                            "spread": "11.9"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Sex: Female, Male",
                "paramType": "COUNT_OF_PARTICIPANTS",
                "unitOfMeasure": "Participants",
                "classes": [
                  {
                    "categories": [
                      {
                        "title": "Female",
                        "measurements": [
                          {
                            "groupId": "BG000",
                            "value": "29"
                          }
                        ]
                      },
                      {
                        "title": "Male",
                        "measurements": [
                          {
                            "groupId": "BG000",
                            "value": "43"
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "outcomeMeasuresModule": {
            "outcomeMeasures": [
              {
                "type": "PRIMARY",
                "title": "Latency To Persistent Sleep (LPS)",
                "description": "The objective measure, LPS, defined as the amount of time measured in minutes it takes to fall asleep was based on polysomnography (PSG) objective assessments of sleep disturbance. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.",
                "populationDescription": "Full analysis set: includes randomized participants who were administered \\>= 1 dose of study medication and had evaluable data for the primary efficacy assessments from any of the 5 treatment intervals.",
                "reportingStatus": "POSTED",
                "paramType": "MEAN",
                "dispersionType": "Standard Deviation",
                "unitOfMeasure": "Minutes",
                "timeFrame": "10 days (5 intervals of two consecutive nights)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Placebo",
                    "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 1 mg",
                    "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg",
                    "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg",
                    "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG004",
                    "title": "Zolpidem Tartrate 10 mg",
                    "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "69"
                      },
                      {
                        "groupId": "OG003",
                        "value": "68"
                      },
                      {
                        "groupId": "OG004",
                        "value": "70"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "37.5",
                            "spread": "37.8"
                          },
                          {
                            "groupId": "OG001",
                            "value": "24.4",
                            "spread": "22.7"
                          },
                          {
                            "groupId": "OG002",
                            "value": "20.9",
                            "spread": "24.3"
                          },
                          {
                            "groupId": "OG003",
                            "value": "12.8",
                            "spread": "11.2"
                          },
                          {
                            "groupId": "OG004",
                            "value": "14.3",
                            "spread": "22.6"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Total Sleep Time (Objective & Subjective)",
                "description": "Total sleep time defined as total sleeping time from bedtime to final awakening (measured in minutes) was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective total sleep time was based on PSG-based assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments of sleep disturbance and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "populationDescription": "Full analysis set: includes randomized participants who were administered \\>= 1 dose of study medication and had evaluable data for the primary efficacy assessments from any of the 5 treatment intervals.",
                "reportingStatus": "POSTED",
                "paramType": "MEDIAN",
                "dispersionType": "Full Range",
                "unitOfMeasure": "Minutes",
                "timeFrame": "10 days (5 intervals of two consecutive nights)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Placebo",
                    "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 1 mg",
                    "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg",
                    "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg",
                    "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG004",
                    "title": "Zolpidem Tartrate 10 mg",
                    "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "69"
                      },
                      {
                        "groupId": "OG003",
                        "value": "68"
                      },
                      {
                        "groupId": "OG004",
                        "value": "70"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Objective Total Sleep Time",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "414.0",
                            "lowerLimit": "279.3",
                            "upperLimit": "470.3"
                          },
                          {
                            "groupId": "OG001",
                            "value": "438.3",
                            "lowerLimit": "292.3",
                            "upperLimit": "468.5"
                          },
                          {
                            "groupId": "OG002",
                            "value": "452.5",
                            "lowerLimit": "227.5",
                            "upperLimit": "475.8"
                          },
                          {
                            "groupId": "OG003",
                            "value": "453.4",
                            "lowerLimit": "313.5",
                            "upperLimit": "474.5"
                          },
                          {
                            "groupId": "OG004",
                            "value": "448.6",
                            "lowerLimit": "338.8",
                            "upperLimit": "476.3"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Subjective Total Sleep Time",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "360.0",
                            "lowerLimit": "90.0",
                            "upperLimit": "452.5"
                          },
                          {
                            "groupId": "OG001",
                            "value": "390.0",
                            "lowerLimit": "225.0",
                            "upperLimit": "460.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "397.5",
                            "lowerLimit": "225.0",
                            "upperLimit": "478.5"
                          },
                          {
                            "groupId": "OG003",
                            "value": "420.0",
                            "lowerLimit": "225.0",
                            "upperLimit": "480.0"
                          },
                          {
                            "groupId": "OG004",
                            "value": "411.3",
                            "lowerLimit": "195.0",
                            "upperLimit": "480.0"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Sleep Efficiency",
                "description": "Sleep efficiency (SE) was an assessment obtained from PSG during the treatment period and was defined as the ratio of total sleep time to the total time in bed of 8 hours \\* 100, expressed as a percent.\n\nPSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the patient's median bedtime as recorded in the sleep diary. During the screening period, participants were provided a diary in which they recorded the time of lights out before bedtime for 1 week pror to PSG evaluations. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.",
                "populationDescription": "Full analysis set: includes randomized participants who were administered \\>= 1 dose of study medication and had evaluable data for the primary efficacy assessments from any of the 5 treatment intervals.",
                "reportingStatus": "POSTED",
                "paramType": "MEDIAN",
                "dispersionType": "Full Range",
                "unitOfMeasure": "Percentage of time asleep of 8 hours",
                "timeFrame": "10 days (5 intervals of two consecutive nights)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Placebo",
                    "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 1 mg",
                    "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg",
                    "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg",
                    "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG004",
                    "title": "Zolpidem Tartrate 10 mg",
                    "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "69"
                      },
                      {
                        "groupId": "OG003",
                        "value": "68"
                      },
                      {
                        "groupId": "OG004",
                        "value": "70"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "86.3",
                            "lowerLimit": "58.2",
                            "upperLimit": "98.0"
                          },
                          {
                            "groupId": "OG001",
                            "value": "91.3",
                            "lowerLimit": "60.9",
                            "upperLimit": "97.6"
                          },
                          {
                            "groupId": "OG002",
                            "value": "94.3",
                            "lowerLimit": "47.4",
                            "upperLimit": "99.2"
                          },
                          {
                            "groupId": "OG003",
                            "value": "94.5",
                            "lowerLimit": "65.3",
                            "upperLimit": "98.9"
                          },
                          {
                            "groupId": "OG004",
                            "value": "93.5",
                            "lowerLimit": "70.6",
                            "upperLimit": "99.3"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Wake Time After Sleep Onset (WASO)- Objective & Subjective",
                "description": "Wake Time After Sleep Onset (WASO) defined as total awakening time from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective WASO was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "populationDescription": "Full analysis set: includes randomized participants who were administered \\>= 1 dose of study medication and had evaluable data for the primary efficacy assessments from any of the 5 treatment intervals.",
                "reportingStatus": "POSTED",
                "paramType": "MEDIAN",
                "dispersionType": "Full Range",
                "unitOfMeasure": "Minutes",
                "timeFrame": "10 days (5 intervals of two consecutive nights)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Placebo",
                    "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 1 mg",
                    "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg",
                    "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg",
                    "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG004",
                    "title": "Zolpidem Tartrate 10 mg",
                    "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "69"
                      },
                      {
                        "groupId": "OG003",
                        "value": "68"
                      },
                      {
                        "groupId": "OG004",
                        "value": "70"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Objective Wake Time After Sleep Onset",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "26.3",
                            "lowerLimit": "1.5",
                            "upperLimit": "164.3"
                          },
                          {
                            "groupId": "OG001",
                            "value": "22.5",
                            "lowerLimit": "1.0",
                            "upperLimit": "144.8"
                          },
                          {
                            "groupId": "OG002",
                            "value": "17.8",
                            "lowerLimit": "0.5",
                            "upperLimit": "176.0"
                          },
                          {
                            "groupId": "OG003",
                            "value": "18.8",
                            "lowerLimit": "0.8",
                            "upperLimit": "165.5"
                          },
                          {
                            "groupId": "OG004",
                            "value": "20.0",
                            "lowerLimit": "1.5",
                            "upperLimit": "139.5"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Subjective Wake Time After Sleep Onset",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "75.0",
                            "lowerLimit": "3.0",
                            "upperLimit": "300.0"
                          },
                          {
                            "groupId": "OG001",
                            "value": "60.0",
                            "lowerLimit": "0.5",
                            "upperLimit": "285.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "37.5",
                            "lowerLimit": "0.0",
                            "upperLimit": "255.0"
                          },
                          {
                            "groupId": "OG003",
                            "value": "40.0",
                            "lowerLimit": "0.0",
                            "upperLimit": "227.5"
                          },
                          {
                            "groupId": "OG004",
                            "value": "50.0",
                            "lowerLimit": "0.0",
                            "upperLimit": "285.0"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Number of Awakenings (Objective & Subjective)",
                "description": "Number of awakenings defined as the total number of spontaneous awakenings from falling asleep to final awakening was objectively determined by polysomnography and subjectively determined based on participant-reported measures following treatment.\n\nThe objective number of awakenings was based on PSG assessments. PSG recording was performed according to a manual for overnight PSG. The start time for PSG recording was individualized and scheduled within +/- 30 minutes of the participant's median bedtime as recorded in the sleep diary. PSG recording duration for scoring was 8 hours. PSG data recorded during treatment were centrally scored by a trained expert.\n\nThe subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "populationDescription": "Full analysis set: includes randomized participants who were administered \\>= 1 dose of study medication and had evaluable data for the primary efficacy assessments from any of the 5 treatment intervals.",
                "reportingStatus": "POSTED",
                "paramType": "MEDIAN",
                "dispersionType": "Full Range",
                "unitOfMeasure": "Number of awakenings",
                "timeFrame": "10 days (5 intervals of two consecutive nights)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Placebo",
                    "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 1 mg",
                    "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg",
                    "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg",
                    "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG004",
                    "title": "Zolpidem Tartrate 10 mg",
                    "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "69"
                      },
                      {
                        "groupId": "OG003",
                        "value": "68"
                      },
                      {
                        "groupId": "OG004",
                        "value": "70"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Objective Number of Awakenings",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "4.0",
                            "lowerLimit": "0.5",
                            "upperLimit": "18.0"
                          },
                          {
                            "groupId": "OG001",
                            "value": "4.0",
                            "lowerLimit": "0.0",
                            "upperLimit": "11.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "3.5",
                            "lowerLimit": "0.0",
                            "upperLimit": "10.0"
                          },
                          {
                            "groupId": "OG003",
                            "value": "2.8",
                            "lowerLimit": "0.0",
                            "upperLimit": "10.0"
                          },
                          {
                            "groupId": "OG004",
                            "value": "3.5",
                            "lowerLimit": "0.5",
                            "upperLimit": "14.0"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Subjective Number of Awakenings",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "3.0",
                            "lowerLimit": "0.0",
                            "upperLimit": "11.0"
                          },
                          {
                            "groupId": "OG001",
                            "value": "3.0",
                            "lowerLimit": "0.5",
                            "upperLimit": "8.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "2.5",
                            "lowerLimit": "0.0",
                            "upperLimit": "6.5"
                          },
                          {
                            "groupId": "OG003",
                            "value": "2.0",
                            "lowerLimit": "0.0",
                            "upperLimit": "8.0"
                          },
                          {
                            "groupId": "OG004",
                            "value": "2.0",
                            "lowerLimit": "0.0",
                            "upperLimit": "6.0"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "PRIMARY",
                "title": "Sleep Latency (SL)",
                "description": "The subjective measure, SL, defined as the amount of time measured in minutes it takes to fall asleep was based on participant-reported subjective assessments of sleep disturbance and was obtained from participants' responses to morning questionnaires. Questionnaires were administered during each visit during the treatment period.",
                "populationDescription": "Full analysis set: includes randomized participants who were administered \\>= 1 dose of study medication and had evaluable data for the primary efficacy assessments from any of the 5 treatment intervals.",
                "reportingStatus": "POSTED",
                "paramType": "MEAN",
                "dispersionType": "Standard Deviation",
                "unitOfMeasure": "Minutes",
                "timeFrame": "10 days (5 intervals of two consecutive nights)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Placebo",
                    "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 1 mg",
                    "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg",
                    "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg",
                    "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  },
                  {
                    "id": "OG004",
                    "title": "Zolpidem Tartrate 10 mg",
                    "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "71"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "69"
                      },
                      {
                        "groupId": "OG003",
                        "value": "68"
                      },
                      {
                        "groupId": "OG004",
                        "value": "70"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "62.0",
                            "spread": "47.8"
                          },
                          {
                            "groupId": "OG001",
                            "value": "45.5",
                            "spread": "36.7"
                          },
                          {
                            "groupId": "OG002",
                            "value": "32.6",
                            "spread": "26.4"
                          },
                          {
                            "groupId": "OG003",
                            "value": "28.4",
                            "spread": "23.8"
                          },
                          {
                            "groupId": "OG004",
                            "value": "28.0",
                            "spread": "24.6"
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "adverseEventsModule": {
            "frequencyThreshold": "2",
            "description": "Safety population included randomized participants who were administered \\>= 1 dose of study medication and had any evaluable safety data.",
            "eventGroups": [
              {
                "id": "EG000",
                "title": "Placebo",
                "description": "Placebo tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns.",
                "seriousNumAffected": 0,
                "seriousNumAtRisk": 71,
                "otherNumAffected": 5,
                "otherNumAtRisk": 71
              },
              {
                "id": "EG001",
                "title": "Eszopiclone 1 mg",
                "description": "Eszopiclone 1 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns.",
                "seriousNumAffected": 0,
                "seriousNumAtRisk": 70,
                "otherNumAffected": 10,
                "otherNumAtRisk": 70
              },
              {
                "id": "EG002",
                "title": "Eszopiclone 2 mg",
                "description": "Eszopiclone 2 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns.",
                "seriousNumAffected": 0,
                "seriousNumAtRisk": 69,
                "otherNumAffected": 10,
                "otherNumAtRisk": 69
              },
              {
                "id": "EG003",
                "title": "Eszopiclone 3 mg",
                "description": "Eszopiclone 3 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns.",
                "seriousNumAffected": 0,
                "seriousNumAtRisk": 68,
                "otherNumAffected": 17,
                "otherNumAtRisk": 68
              },
              {
                "id": "EG004",
                "title": "Zolpidem Tartrate 10 mg",
                "description": "Zolpidem Tartrate 10 mg tablet taken orally at bedtime for 2 consecutive nights in one of 5 cross-over intervals in each of 10 prespecified treatment sequence patterns.",
                "seriousNumAffected": 0,
                "seriousNumAtRisk": 70,
                "otherNumAffected": 8,
                "otherNumAtRisk": 70
              }
            ],
            "otherEvents": [
              {
                "term": "Dysgeusia",
                "organSystem": "Nervous system disorders",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 1,
                    "numAtRisk": 71
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 4,
                    "numAtRisk": 70
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 6,
                    "numAtRisk": 69
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 11,
                    "numAtRisk": 68
                  },
                  {
                    "groupId": "EG004",
                    "numAffected": 1,
                    "numAtRisk": 70
                  }
                ]
              },
              {
                "term": "Somnolence",
                "organSystem": "Nervous system disorders",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 71
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 70
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 3,
                    "numAtRisk": 69
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 4,
                    "numAtRisk": 68
                  },
                  {
                    "groupId": "EG004",
                    "numAffected": 3,
                    "numAtRisk": 70
                  }
                ]
              },
              {
                "term": "Dizziness",
                "organSystem": "Nervous system disorders",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 71
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 70
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 69
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 68
                  },
                  {
                    "groupId": "EG004",
                    "numAffected": 3,
                    "numAtRisk": 70
                  }
                ]
              },
              {
                "term": "Dermatitis Contact",
                "organSystem": "Skin and subcutaneous tissue disorders",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 71
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 70
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 69
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 68
                  },
                  {
                    "groupId": "EG004",
                    "numAffected": 1,
                    "numAtRisk": 70
                  }
                ]
              },
              {
                "term": "Feeling Abnormal",
                "organSystem": "General disorders",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 71
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 3,
                    "numAtRisk": 70
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 69
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 68
                  },
                  {
                    "groupId": "EG004",
                    "numAffected": 0,
                    "numAtRisk": 70
                  }
                ]
              }
            ]
          },
          "moreInfoModule": {
            "certainAgreement": {
              "piSponsorEmployee": false,
              "restrictiveAgreement": false
            },
            "pointOfContact": {
              "title": "Atsushi Kamijo, Study Director",
              "organization": "Eisai Co., Ltd.",
              "email": "a-kamijo@hhc.eisai.co.jp",
              "phone": "+81-3-3817-5245"
            }
          }
        },
        "derivedSection": {
          "miscInfoModule": {
            "versionHolder": "2024-12-20"
          },
          "conditionBrowseModule": {
            "meshes": [
              {
                "id": "D007319",
                "term": "Sleep Initiation and Maintenance Disorders"
              }
            ],
            "ancestors": [
              {
                "id": "D020919",
                "term": "Sleep Disorders, Intrinsic"
              },
              {
                "id": "D020920",
                "term": "Dyssomnias"
              },
              {
                "id": "D012893",
                "term": "Sleep Wake Disorders"
              },
              {
                "id": "D009422",
                "term": "Nervous System Diseases"
              },
              {
                "id": "D001523",
                "term": "Mental Disorders"
              }
            ],
            "browseLeaves": [
              {
                "id": "M10356",
                "name": "Sleep Initiation and Maintenance Disorders",
                "asFound": "Primary Insomnia",
                "relevance": "HIGH"
              },
              {
                "id": "M22242",
                "name": "Parasomnias",
                "relevance": "LOW"
              },
              {
                "id": "M22654",
                "name": "Sleep Disorders, Intrinsic",
                "relevance": "LOW"
              },
              {
                "id": "M22655",
                "name": "Dyssomnias",
                "relevance": "LOW"
              },
              {
                "id": "M15696",
                "name": "Sleep Wake Disorders",
                "relevance": "LOW"
              },
              {
                "id": "M14473",
                "name": "Psychotic Disorders",
                "relevance": "LOW"
              },
              {
                "id": "M4815",
                "name": "Mental Disorders",
                "relevance": "LOW"
              }
            ],
            "browseBranches": [
              {
                "abbrev": "BC10",
                "name": "Nervous System Diseases"
              },
              {
                "abbrev": "BXM",
                "name": "Behaviors and Mental Disorders"
              },
              {
                "abbrev": "All",
                "name": "All Conditions"
              },
              {
                "abbrev": "BC23",
                "name": "Symptoms and General Pathology"
              }
            ]
          },
          "interventionBrowseModule": {
            "meshes": [
              {
                "id": "D000077334",
                "term": "Zolpidem"
              },
              {
                "id": "D000069582",
                "term": "Eszopiclone"
              }
            ],
            "ancestors": [
              {
                "id": "D000068776",
                "term": "Sleep Aids, Pharmaceutical"
              },
              {
                "id": "D006993",
                "term": "Hypnotics and Sedatives"
              },
              {
                "id": "D002492",
                "term": "Central Nervous System Depressants"
              },
              {
                "id": "D045505",
                "term": "Physiological Effects of Drugs"
              },
              {
                "id": "D058785",
                "term": "GABA-A Receptor Agonists"
              },
              {
                "id": "D018755",
                "term": "GABA Agonists"
              },
              {
                "id": "D018682",
                "term": "GABA Agents"
              },
              {
                "id": "D018377",
                "term": "Neurotransmitter Agents"
              },
              {
                "id": "D045504",
                "term": "Molecular Mechanisms of Pharmacological Action"
              }
            ],
            "browseLeaves": [
              {
                "id": "M1771",
                "name": "Zolpidem",
                "asFound": "NK/T-cell lymphoma",
                "relevance": "HIGH"
              },
              {
                "id": "M475",
                "name": "Eszopiclone",
                "asFound": "Atomoxetine",
                "relevance": "HIGH"
              },
              {
                "id": "M7338",
                "name": "Diphenhydramine",
                "relevance": "LOW"
              },
              {
                "id": "M14268",
                "name": "Promethazine",
                "relevance": "LOW"
              },
              {
                "id": "M10043",
                "name": "Hypnotics and Sedatives",
                "relevance": "LOW"
              },
              {
                "id": "M20825",
                "name": "GABA Agonists",
                "relevance": "LOW"
              },
              {
                "id": "M20504",
                "name": "Neurotransmitter Agents",
                "relevance": "LOW"
              }
            ],
            "browseBranches": [
              {
                "abbrev": "CNSDep",
                "name": "Central Nervous System Depressants"
              },
              {
                "abbrev": "All",
                "name": "All Drugs and Chemicals"
              },
              {
                "abbrev": "AAll",
                "name": "Anti-Allergic Agents"
              },
              {
                "abbrev": "AnEm",
                "name": "Antiemetics"
              },
              {
                "abbrev": "Gast",
                "name": "Gastrointestinal Agents"
              },
              {
                "abbrev": "Derm",
                "name": "Dermatologic Agents"
              }
            ]
          }
        },
        "hasResults": true
      },
      {
        "protocolSection": {
          "identificationModule": {
            "nctId": "NCT00770692",
            "orgStudyIdInfo": {
              "id": "190-150"
            },
            "organization": {
              "fullName": "Eisai Inc.",
              "class": "INDUSTRY"
            },
            "briefTitle": "A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)",
            "officialTitle": "A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia"
          },
          "statusModule": {
            "statusVerifiedDate": "2012-10",
            "overallStatus": "COMPLETED",
            "expandedAccessInfo": {
              "hasExpandedAccess": false
            },
            "startDateStruct": {
              "date": "2008-10"
            },
            "primaryCompletionDateStruct": {
              "date": "2010-05",
              "type": "ACTUAL"
            },
            "completionDateStruct": {
              "date": "2010-05",
              "type": "ACTUAL"
            },
            "studyFirstSubmitDate": "2008-10-09",
            "studyFirstSubmitQcDate": "2008-10-09",
            "studyFirstPostDateStruct": {
              "date": "2008-10-10",
              "type": "ESTIMATED"
            },
            "resultsFirstSubmitDate": "2012-10-24",
            "resultsFirstSubmitQcDate": "2012-10-24",
            "resultsFirstPostDateStruct": {
              "date": "2012-11-22",
              "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2012-10-24",
            "lastUpdatePostDateStruct": {
              "date": "2012-11-22",
              "type": "ESTIMATED"
            }
          },
          "sponsorCollaboratorsModule": {
            "responsibleParty": {
              "type": "SPONSOR"
            },
            "leadSponsor": {
              "name": "Eisai Co., Ltd.",
              "class": "INDUSTRY"
            }
          },
          "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.",
            "detailedDescription": "This is a multicenter, randomized, double-blinded study to evaluate the long-term safety of SEP-190 (2, 3 mg) in non-elderly patients with insomnia and SEP-190 (1, 2 mg) in elderly patients with insomnia."
          },
          "conditionsModule": {
            "conditions": [
              "Insomnia"
            ],
            "keywords": [
              "insomnia",
              "primary insomnia",
              "insomnia associated with psychiatric or physical disorder(s)"
            ]
          },
          "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
              "PHASE3"
            ],
            "designInfo": {
              "allocation": "RANDOMIZED",
              "interventionModel": "PARALLEL",
              "primaryPurpose": "TREATMENT",
              "maskingInfo": {
                "masking": "DOUBLE",
                "whoMasked": [
                  "PARTICIPANT",
                  "INVESTIGATOR"
                ]
              }
            },
            "enrollmentInfo": {
              "count": 369,
              "type": "ACTUAL"
            }
          },
          "armsInterventionsModule": {
            "armGroups": [
              {
                "label": "Eszopiclone 1 mg- Elderly",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 1 mg- Elderly"
                ]
              },
              {
                "label": "Eszopiclone 2 mg- Elderly",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 2 mg- Elderly"
                ]
              },
              {
                "label": "Eszopiclone 2 mg- Non-elderly",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 2 mg- Non-elderly"
                ]
              },
              {
                "label": "Eszopiclone 3 mg- Non-elderly",
                "type": "EXPERIMENTAL",
                "interventionNames": [
                  "Drug: Eszopiclone 3 mg- Non-elderly"
                ]
              }
            ],
            "interventions": [
              {
                "type": "DRUG",
                "name": "Eszopiclone 1 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.",
                "armGroupLabels": [
                  "Eszopiclone 1 mg- Elderly"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              },
              {
                "type": "DRUG",
                "name": "Eszopiclone 2 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.",
                "armGroupLabels": [
                  "Eszopiclone 2 mg- Elderly"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              },
              {
                "type": "DRUG",
                "name": "Eszopiclone 3 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.",
                "armGroupLabels": [
                  "Eszopiclone 3 mg- Non-elderly"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              },
              {
                "type": "DRUG",
                "name": "Eszopiclone 2 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.",
                "armGroupLabels": [
                  "Eszopiclone 2 mg- Non-elderly"
                ],
                "otherNames": [
                  "SEP-190"
                ]
              }
            ]
          },
          "outcomesModule": {
            "primaryOutcomes": [
              {
                "measure": "Incidence of Adverse Events",
                "description": "Incidence of adverse events was defined as: (number of participants with adverse events/ number of participants analyzed in the safety analysis set)\\*100.\n\nAn adverse event was defined as any unwanted or untoward disease or its symptom, sign, or abnormality in laboratory parameters in a subject who receives a study drug. An adverse event does not necessarily have a causal relationship with the study drug. The investigator or subinvestigator evaluated adverse events and recorded the results in the case report form (CRF). The investigator or subinvestigator recorded all adverse events occurring after the start of study treatment in the CRF, irrespective of the causal relationship with the study drug or the study procedures. All data collected from the follow-up was recorded in CRF.",
                "timeFrame": "Up to 25 weeks (24 weeks treatment period & 1 week follow-up)"
              }
            ],
            "secondaryOutcomes": [
              {
                "measure": "Mean Change From Baseline In Sleep Latency",
                "description": "Based on subjective symptoms, the participants recorded their sleep latency (the amount of time measured in minutes it takes to fall asleep) in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the sleep latency of the overall period assessment - sleep latency at baseline (screening period).",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment"
              },
              {
                "measure": "Mean Change From Baseline in Wake Time After Sleep Onset (WASO)",
                "description": "Based on subjective symptoms, the participants recorded their WASO defined as total awakening time from falling asleep to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the WASO of the overall period assessment - WASO at baseline (screening period).",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment"
              },
              {
                "measure": "Mean Change From Baseline in Total Sleep Time",
                "description": "Based on subjective symptoms, the participants recorded their total sleep time defined as total sleeping time from bedtime to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the total sleep time of the overall period assessment - total sleep time at baseline (screening period).",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment"
              },
              {
                "measure": "Mean Change From Baseline in Total Number of Awakenings",
                "description": "Based on subjective symptoms, the participants recorded their number of awakenings defined as total number of spontaneous awakenings from falling asleep to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the total number of awakenings of the overall period assessment - total number of awakenings at baseline (screening period).",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment"
              }
            ]
          },
          "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\n1. Participants who submit written informed consent for study entry.\n2. Participants aged greater than or equal to 20 and less than 85 years of age at the time of obtaining informed consent.\n3. Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version or diagnosed with insomnia associated with psychiatric or physical disorder(s).\n4. Participants with both of the following conditions which are persistent for 4 weeks or longer before the start of observation period:\n\n   * Total sleep time is less than or equal to 390 minutes for more than or equal to 3 days a week\n   * Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week\n5. Participants with data at least 2 consecutive days in diary entries during observation period and confirmed to meet the following two criteria:\n\n   * Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week\n   * Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week\n\nExclusion criteria:\n\n1. Participants with a present or history of the following disease specified in\n\n   Mini-International Neuropsychiatric Interview (M.I.N.I.) Japanese version 5.0:\n   * Risk of suicide\n   * (Mild) manic episode\n   * Post-traumatic stress disorder (PTSD)\n   * Alcohol dependence and abuse\n   * Drug (non-alcohol) dependence and abuse\n   * Anorexia nervosa\n   * Bulimia nervosa\n   * Anti-social personality disorder\n2. Participants with pharmacologically induced insomnia (drug-induced insomnia).\n3. Participants with comorbid primary sleep disorders (circadian rhythm disorder, restless legs movement syndrome, periodic limb movement disorder, sleep apnea syndrome, etc.) other than primary insomnia.\n4. Participants with symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturation, and cough.\n5. Participants with unstable primary disease presenting insomnia during 4 weeks before the start of observation period.\n6. Participants with organic mental disorder.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "20 Years",
            "maximumAge": "84 Years",
            "stdAges": [
              "ADULT",
              "OLDER_ADULT"
            ]
          },
          "contactsLocationsModule": {
            "overallOfficials": [
              {
                "name": "Atsushi Kamijo",
                "affiliation": "New Product Development Department, Clinical Research Center",
                "role": "STUDY_DIRECTOR"
              }
            ],
            "locations": [
              {
                "city": "Nagoya",
                "state": "Aichi",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.18147,
                  "lon": 136.90641
                }
              },
              {
                "city": "Iizuka",
                "state": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.63654,
                  "lon": 130.68678
                }
              },
              {
                "city": "Kitakyushu",
                "state": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.85181,
                  "lon": 130.85034
                }
              },
              {
                "city": "Kurume",
                "state": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.31667,
                  "lon": 130.51667
                }
              },
              {
                "city": "Onga",
                "state": "Fukuoka",
                "country": "Japan"
              },
              {
                "city": "Maebashi",
                "state": "Gunma",
                "country": "Japan",
                "geoPoint": {
                  "lat": 36.4,
                  "lon": 139.08333
                }
              },
              {
                "city": "Sapporo",
                "state": "Hokkaido",
                "country": "Japan",
                "geoPoint": {
                  "lat": 43.06667,
                  "lon": 141.35
                }
              },
              {
                "city": "Itami",
                "state": "Hyogo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.78427,
                  "lon": 135.40126
                }
              },
              {
                "city": "Yokohama",
                "state": "Kanagawa",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.43333,
                  "lon": 139.65
                }
              },
              {
                "city": "Yokoyama",
                "state": "Kanagawa",
                "country": "Japan"
              },
              {
                "city": "Kashiba",
                "state": "Nara",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.53472,
                  "lon": 135.70925
                }
              },
              {
                "city": "Urazoe",
                "state": "Okinawa",
                "country": "Japan",
                "geoPoint": {
                  "lat": 26.25444,
                  "lon": 127.70639
                }
              },
              {
                "city": "Ibaragi",
                "state": "Osaka",
                "country": "Japan"
              },
              {
                "city": "Kishiwada",
                "state": "Osaka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.46667,
                  "lon": 135.36667
                }
              },
              {
                "city": "Fujimi",
                "state": "Saitama",
                "country": "Japan"
              },
              {
                "city": "Kusatsu",
                "state": "Shiga",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.01667,
                  "lon": 135.96667
                }
              },
              {
                "city": "Arakawa-ku",
                "state": "Tokyo",
                "country": "Japan"
              },
              {
                "city": "Chuo-ku",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.57779,
                  "lon": 139.71685
                }
              },
              {
                "city": "Edogawa-ku",
                "state": "Tokyo",
                "country": "Japan"
              },
              {
                "city": "Kodaira",
                "state": "Tokyo",
                "country": "Japan"
              },
              {
                "city": "Koto-ku",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.66667,
                  "lon": 139.81718
                }
              },
              {
                "city": "Minato-ku",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.2152,
                  "lon": 135.1501
                }
              },
              {
                "city": "Musashino",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.70611,
                  "lon": 139.55944
                }
              },
              {
                "city": "Ota-ku",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 36.3,
                  "lon": 139.36667
                }
              },
              {
                "city": "Shinagawa-ku",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.63627,
                  "lon": 133.00572
                }
              },
              {
                "city": "Shinjuku-ku",
                "state": "Tokyo",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.2946,
                  "lon": 139.57059
                }
              },
              {
                "city": "Toshima-ku",
                "state": "Tokyo",
                "country": "Japan"
              },
              {
                "city": "Sagamihara",
                "state": "Yokohama",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.54899,
                  "lon": 139.26064
                }
              },
              {
                "city": "Akita",
                "country": "Japan",
                "geoPoint": {
                  "lat": 39.71667,
                  "lon": 140.10826
                }
              },
              {
                "city": "Fukuoka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.6,
                  "lon": 130.41667
                }
              },
              {
                "city": "Kochi",
                "country": "Japan",
                "geoPoint": {
                  "lat": 33.55,
                  "lon": 133.53333
                }
              },
              {
                "city": "Kumamoto",
                "country": "Japan",
                "geoPoint": {
                  "lat": 32.80589,
                  "lon": 130.69182
                }
              },
              {
                "city": "Kyoto",
                "country": "Japan",
                "geoPoint": {
                  "lat": 35.02107,
                  "lon": 135.75385
                }
              },
              {
                "city": "Osaka",
                "country": "Japan",
                "geoPoint": {
                  "lat": 34.69374,
                  "lon": 135.50218
                }
              }
            ]
          },
          "referencesModule": {
            "references": [
              {
                "pmid": "22731653",
                "type": "DERIVED",
                "citation": "Uchimura N, Kamijo A, Takase T. Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study. Ann Gen Psychiatry. 2012 Jun 25;11(1):15. doi: 10.1186/1744-859X-11-15."
              }
            ]
          }
        },
        "resultsSection": {
          "participantFlowModule": {
            "preAssignmentDetails": "181 non-elderly \\& 188 elderly participants were enrolled in the screening period 1 week prior to the first dose. Among these, 20 non-elderly \\& 24 elderly participants discontinued during the screening period. 161 non-elderly and 164 elderly participants enrolled. 1 elderly participant enrolled for treatment did not receive treatment.",
            "groups": [
              {
                "id": "FG000",
                "title": "Eszopiclone 1 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
              },
              {
                "id": "FG001",
                "title": "Eszopiclone 2 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
              },
              {
                "id": "FG002",
                "title": "Eszopiclone 2 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
              },
              {
                "id": "FG003",
                "title": "Eszopiclone 3 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
              }
            ],
            "periods": [
              {
                "title": "Overall Study",
                "milestones": [
                  {
                    "type": "STARTED",
                    "achievements": [
                      {
                        "groupId": "FG000",
                        "comment": "1 participant whose compliance was unknown, was regarded as a \"treatment compliance unknown\"",
                        "numSubjects": "81"
                      },
                      {
                        "groupId": "FG001",
                        "numSubjects": "83"
                      },
                      {
                        "groupId": "FG002",
                        "numSubjects": "84"
                      },
                      {
                        "groupId": "FG003",
                        "numSubjects": "77"
                      }
                    ]
                  },
                  {
                    "type": "COMPLETED",
                    "achievements": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "69"
                      },
                      {
                        "groupId": "FG001",
                        "numSubjects": "74"
                      },
                      {
                        "groupId": "FG002",
                        "numSubjects": "70"
                      },
                      {
                        "groupId": "FG003",
                        "numSubjects": "66"
                      }
                    ]
                  },
                  {
                    "type": "NOT COMPLETED",
                    "achievements": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "12"
                      },
                      {
                        "groupId": "FG001",
                        "numSubjects": "9"
                      },
                      {
                        "groupId": "FG002",
                        "numSubjects": "14"
                      },
                      {
                        "groupId": "FG003",
                        "numSubjects": "11"
                      }
                    ]
                  }
                ],
                "dropWithdraws": [
                  {
                    "type": "Withdrawal by Subject",
                    "reasons": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "7"
                      },
                      {
                        "groupId": "FG001",
                        "numSubjects": "9"
                      },
                      {
                        "groupId": "FG002",
                        "numSubjects": "9"
                      },
                      {
                        "groupId": "FG003",
                        "numSubjects": "6"
                      }
                    ]
                  },
                  {
                    "type": "Adverse Event",
                    "reasons": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "3"
                      },
                      {
                        "groupId": "FG001",
                        "numSubjects": "0"
                      },
                      {
                        "groupId": "FG002",
                        "numSubjects": "4"
                      },
                      {
                        "groupId": "FG003",
                        "numSubjects": "4"
                      }
                    ]
                  },
                  {
                    "type": "Investigator judgment",
                    "reasons": [
                      {
                        "groupId": "FG000",
                        "numSubjects": "2"
                      },
                      {
                        "groupId": "FG001",
                        "numSubjects": "0"
                      },
                      {
                        "groupId": "FG002",
                        "numSubjects": "1"
                      },
                      {
                        "groupId": "FG003",
                        "numSubjects": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "baselineCharacteristicsModule": {
            "groups": [
              {
                "id": "BG000",
                "title": "Eszopiclone 1 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
              },
              {
                "id": "BG001",
                "title": "Eszopiclone 2 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
              },
              {
                "id": "BG002",
                "title": "Eszopiclone 2 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
              },
              {
                "id": "BG003",
                "title": "Eszopiclone 3 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
              },
              {
                "id": "BG004",
                "title": "Total",
                "description": "Total of all reporting groups"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "BG000",
                    "value": "80"
                  },
                  {
                    "groupId": "BG001",
                    "value": "83"
                  },
                  {
                    "groupId": "BG002",
                    "value": "84"
                  },
                  {
                    "groupId": "BG003",
                    "value": "77"
                  },
                  {
                    "groupId": "BG004",
                    "value": "324"
                  }
                ]
              }
            ],
            "measures": [
              {
                "title": "Age Continuous",
                "paramType": "MEAN",
                "dispersionType": "STANDARD_DEVIATION",
                "unitOfMeasure": "years",
                "classes": [
                  {
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "BG000",
                            "value": "70.4",
                            "spread": "4.5"
                          },
                          {
                            "groupId": "BG001",
                            "value": "70.7",
                            "spread": "4.7"
                          },
                          {
                            "groupId": "BG002",
                            "value": "40.1",
                            "spread": "10.8"
                          },
                          {
                            "groupId": "BG003",
                            "value": "41.9",
                            "spread": "11.5"
                          },
                          {
                            "groupId": "BG004",
                            "value": "55.6",
                            "spread": "17.1"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Sex: Female, Male",
                "paramType": "COUNT_OF_PARTICIPANTS",
                "unitOfMeasure": "Participants",
                "classes": [
                  {
                    "categories": [
                      {
                        "title": "Female",
                        "measurements": [
                          {
                            "groupId": "BG000",
                            "value": "45"
                          },
                          {
                            "groupId": "BG001",
                            "value": "49"
                          },
                          {
                            "groupId": "BG002",
                            "value": "55"
                          },
                          {
                            "groupId": "BG003",
                            "value": "36"
                          },
                          {
                            "groupId": "BG004",
                            "value": "185"
                          }
                        ]
                      },
                      {
                        "title": "Male",
                        "measurements": [
                          {
                            "groupId": "BG000",
                            "value": "35"
                          },
                          {
                            "groupId": "BG001",
                            "value": "34"
                          },
                          {
                            "groupId": "BG002",
                            "value": "29"
                          },
                          {
                            "groupId": "BG003",
                            "value": "41"
                          },
                          {
                            "groupId": "BG004",
                            "value": "139"
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "outcomeMeasuresModule": {
            "outcomeMeasures": [
              {
                "type": "SECONDARY",
                "title": "Mean Change From Baseline In Sleep Latency",
                "description": "Based on subjective symptoms, the participants recorded their sleep latency (the amount of time measured in minutes it takes to fall asleep) in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the sleep latency of the overall period assessment - sleep latency at baseline (screening period).",
                "populationDescription": "Efficacy analysis set: all of the 161 non-elderly participants who were enrolled in the treatment period. Among the 164 elderly participants who were enrolled in the treatment period, 163 (80 in the 1 mg group and 83 in the 2 mg group) were included in the efficacy set, excluding 1 participant in the 1 mg group who had no evaluable efficacy data.",
                "reportingStatus": "POSTED",
                "paramType": "MEAN",
                "dispersionType": "Standard Deviation",
                "unitOfMeasure": "minutes",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Eszopiclone 1 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 2 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "80"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      },
                      {
                        "groupId": "OG002",
                        "value": "84"
                      },
                      {
                        "groupId": "OG003",
                        "value": "77"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Baseline",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "65.5",
                            "spread": "40.5"
                          },
                          {
                            "groupId": "OG001",
                            "value": "70.7",
                            "spread": "47.1"
                          },
                          {
                            "groupId": "OG002",
                            "value": "71.8",
                            "spread": "53.5"
                          },
                          {
                            "groupId": "OG003",
                            "value": "64.0",
                            "spread": "42.2"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Overall Period (Change From Baseline)",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "-32.1",
                            "spread": "35.6"
                          },
                          {
                            "groupId": "OG001",
                            "value": "-37.0",
                            "spread": "42.7"
                          },
                          {
                            "groupId": "OG002",
                            "value": "-36.7",
                            "spread": "51.8"
                          },
                          {
                            "groupId": "OG003",
                            "value": "-32.8",
                            "spread": "35.4"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "PRIMARY",
                "title": "Incidence of Adverse Events",
                "description": "Incidence of adverse events was defined as: (number of participants with adverse events/ number of participants analyzed in the safety analysis set)\\*100.\n\nAn adverse event was defined as any unwanted or untoward disease or its symptom, sign, or abnormality in laboratory parameters in a subject who receives a study drug. An adverse event does not necessarily have a causal relationship with the study drug. The investigator or subinvestigator evaluated adverse events and recorded the results in the case report form (CRF). The investigator or subinvestigator recorded all adverse events occurring after the start of study treatment in the CRF, irrespective of the causal relationship with the study drug or the study procedures. All data collected from the follow-up was recorded in CRF.",
                "populationDescription": "Safety analysis set: All 161 non-elderly participants who were enrolled in the treatment period were included. All 164 elderly patients who were enrolled in the treatment period were included. The participant who was excluded from the efficacy analysis set was included in the safety analysis set because the participant had evaluable safety data.",
                "reportingStatus": "POSTED",
                "paramType": "NUMBER",
                "unitOfMeasure": "Percentage of Participants",
                "timeFrame": "Up to 25 weeks (24 weeks treatment period & 1 week follow-up)",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Eszopiclone 1 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 2 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "81"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      },
                      {
                        "groupId": "OG002",
                        "value": "84"
                      },
                      {
                        "groupId": "OG003",
                        "value": "77"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "81.5"
                          },
                          {
                            "groupId": "OG001",
                            "value": "79.5"
                          },
                          {
                            "groupId": "OG002",
                            "value": "82.1"
                          },
                          {
                            "groupId": "OG003",
                            "value": "87.0"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Mean Change From Baseline in Wake Time After Sleep Onset (WASO)",
                "description": "Based on subjective symptoms, the participants recorded their WASO defined as total awakening time from falling asleep to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the WASO of the overall period assessment - WASO at baseline (screening period).",
                "populationDescription": "Efficacy analysis set: all of the 161 non-elderly participants who were enrolled in the treatment period. Among the 164 elderly participants who were enrolled in the treatment period, 163 (80 in the 1 mg group and 83 in the 2 mg group) were included in the efficacy set, excluding 1 participant in the 1 mg group who had no evaluable efficacy data.",
                "reportingStatus": "POSTED",
                "paramType": "MEAN",
                "dispersionType": "Standard Deviation",
                "unitOfMeasure": "minutes",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Eszopiclone 1 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 2 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "80"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      },
                      {
                        "groupId": "OG002",
                        "value": "84"
                      },
                      {
                        "groupId": "OG003",
                        "value": "77"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Baseline",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "61.6",
                            "spread": "52.3"
                          },
                          {
                            "groupId": "OG001",
                            "value": "68.8",
                            "spread": "63.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "53.2",
                            "spread": "41.8"
                          },
                          {
                            "groupId": "OG003",
                            "value": "42.3",
                            "spread": "40.8"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Overall Period (Change From Baseline)",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "-30.8",
                            "spread": "39.9"
                          },
                          {
                            "groupId": "OG001",
                            "value": "-35.1",
                            "spread": "-25.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "-32.4",
                            "spread": "36.9"
                          },
                          {
                            "groupId": "OG003",
                            "value": "-23.3",
                            "spread": "31.1"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Mean Change From Baseline in Total Sleep Time",
                "description": "Based on subjective symptoms, the participants recorded their total sleep time defined as total sleeping time from bedtime to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the total sleep time of the overall period assessment - total sleep time at baseline (screening period).",
                "populationDescription": "Efficacy analysis set: all of the 161 non-elderly participants who were enrolled in the treatment period. Among the 164 elderly participants who were enrolled in the treatment period, 163 (80 in the 1 mg group and 83 in the 2 mg group) were included in the efficacy set, excluding 1 participant in the 1 mg group who had no evaluable efficacy data.",
                "reportingStatus": "POSTED",
                "paramType": "MEAN",
                "dispersionType": "Standard Deviation",
                "unitOfMeasure": "minutes",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Eszopiclone 1 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 2 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "80"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      },
                      {
                        "groupId": "OG002",
                        "value": "84"
                      },
                      {
                        "groupId": "OG003",
                        "value": "77"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Baseline",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "314.2",
                            "spread": "73.2"
                          },
                          {
                            "groupId": "OG001",
                            "value": "307.9",
                            "spread": "60.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "290.7",
                            "spread": "44.0"
                          },
                          {
                            "groupId": "OG003",
                            "value": "308.2",
                            "spread": "57.7"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Overall Period (Change From Baseline)",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "63.6",
                            "spread": "64.1"
                          },
                          {
                            "groupId": "OG001",
                            "value": "74.2",
                            "spread": "61.4"
                          },
                          {
                            "groupId": "OG002",
                            "value": "70.2",
                            "spread": "50.2"
                          },
                          {
                            "groupId": "OG003",
                            "value": "61.8",
                            "spread": "54.7"
                          }
                        ]
                      }
                    ]
                  }
                ]
              },
              {
                "type": "SECONDARY",
                "title": "Mean Change From Baseline in Total Number of Awakenings",
                "description": "Based on subjective symptoms, the participants recorded their number of awakenings defined as total number of spontaneous awakenings from falling asleep to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit. For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period. A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period. The change was calculated as the total number of awakenings of the overall period assessment - total number of awakenings at baseline (screening period).",
                "populationDescription": "Efficacy analysis set: all of the 161 non-elderly participants who were enrolled in the treatment period. Among the 164 elderly participants who were enrolled in the treatment period, 163 (80 in the 1 mg group and 83 in the 2 mg group) were included in the efficacy set, excluding 1 participant in the 1 mg group who had no evaluable efficacy data.",
                "reportingStatus": "POSTED",
                "paramType": "MEAN",
                "dispersionType": "Standard Deviation",
                "unitOfMeasure": "Number of Awakenings",
                "timeFrame": "Baseline (screening period) and 4 weeks of treatment",
                "groups": [
                  {
                    "id": "OG000",
                    "title": "Eszopiclone 1 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG001",
                    "title": "Eszopiclone 2 mg- Elderly",
                    "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  },
                  {
                    "id": "OG002",
                    "title": "Eszopiclone 2 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
                  },
                  {
                    "id": "OG003",
                    "title": "Eszopiclone 3 mg- Non-elderly",
                    "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
                  }
                ],
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "80"
                      },
                      {
                        "groupId": "OG001",
                        "value": "83"
                      },
                      {
                        "groupId": "OG002",
                        "value": "84"
                      },
                      {
                        "groupId": "OG003",
                        "value": "77"
                      }
                    ]
                  }
                ],
                "classes": [
                  {
                    "title": "Baseline",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "1.8",
                            "spread": "0.9"
                          },
                          {
                            "groupId": "OG001",
                            "value": "1.9",
                            "spread": "1.0"
                          },
                          {
                            "groupId": "OG002",
                            "value": "1.7",
                            "spread": "0.9"
                          },
                          {
                            "groupId": "OG003",
                            "value": "1.6",
                            "spread": "1.1"
                          }
                        ]
                      }
                    ]
                  },
                  {
                    "title": "Overall Period (Change From Baseline)",
                    "categories": [
                      {
                        "measurements": [
                          {
                            "groupId": "OG000",
                            "value": "-0.5",
                            "spread": "0.7"
                          },
                          {
                            "groupId": "OG001",
                            "value": "-0.5",
                            "spread": "0.8"
                          },
                          {
                            "groupId": "OG002",
                            "value": "-0.7",
                            "spread": "0.9"
                          },
                          {
                            "groupId": "OG003",
                            "value": "-0.7",
                            "spread": "0.9"
                          }
                        ]
                      }
                    ]
                  }
                ]
              }
            ]
          },
          "adverseEventsModule": {
            "frequencyThreshold": "2",
            "eventGroups": [
              {
                "id": "EG000",
                "title": "Eszopiclone 2 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.",
                "seriousNumAffected": 2,
                "seriousNumAtRisk": 84,
                "otherNumAffected": 69,
                "otherNumAtRisk": 84
              },
              {
                "id": "EG001",
                "title": "Eszopiclone 3 mg- Non-elderly",
                "description": "Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.",
                "seriousNumAffected": 2,
                "seriousNumAtRisk": 77,
                "otherNumAffected": 67,
                "otherNumAtRisk": 77
              },
              {
                "id": "EG002",
                "title": "Eszopiclone 1 mg- Elderly",
                "description": "Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.",
                "seriousNumAffected": 3,
                "seriousNumAtRisk": 81,
                "otherNumAffected": 66,
                "otherNumAtRisk": 81
              },
              {
                "id": "EG003",
                "title": "Eszopiclone 2 mg Elderly",
                "description": "Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.\n\nDose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.",
                "seriousNumAffected": 3,
                "seriousNumAtRisk": 83,
                "otherNumAffected": 66,
                "otherNumAtRisk": 83
              }
            ],
            "seriousEvents": [
              {
                "term": "Appendicitis",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Acute myocardial infarction",
                "organSystem": "Cardiac disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Clavicle fracture",
                "organSystem": "Musculoskeletal and connective tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Completed suicide",
                "organSystem": "Psychiatric disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Type 1 diabetes mellitus",
                "organSystem": "Endocrine disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Major depressive disorder",
                "organSystem": "Psychiatric disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Sick sinus syndrome",
                "organSystem": "Cardiac disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Loss of consciousness",
                "organSystem": "Nervous system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Oesophagitis haemorrhagic",
                "organSystem": "Vascular disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Angina pectoris",
                "organSystem": "Vascular disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Calculus ureteric",
                "organSystem": "Renal and urinary disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Heat illness",
                "organSystem": "Injury, poisoning and procedural complications",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numEvents": 1,
                    "numAffected": 1,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numEvents": 0,
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              }
            ],
            "otherEvents": [
              {
                "term": "Dysgeusia",
                "organSystem": "Nervous system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 36,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 44,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 15,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 23,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Nasopharyngitis",
                "organSystem": "Infections and infestations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 22,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 14,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 14,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 18,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Headache",
                "organSystem": "Nervous system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 3,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 4,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 5,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Somnolence",
                "organSystem": "Nervous system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 3,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 6,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 4,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Upper respiratory tract infection",
                "organSystem": "Infections and infestations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 4,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 4,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 3,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Back pain",
                "organSystem": "Musculoskeletal and connective tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 4,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 3,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Blood creatine phosphokinase increased",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 3,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 4,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Thirst",
                "organSystem": "General disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 3,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Glucose urine present",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 3,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Dizziness",
                "organSystem": "Nervous system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 4,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Pharyngitis",
                "organSystem": "Infections and infestations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 3,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Anaemia",
                "organSystem": "Blood and lymphatic system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Abdominal discomfort",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Gastritis",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 3,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Stomatitis",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 3,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Abdominal Pain",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Abdominal Pain Upper",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Oral Discomfort",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Reflux Oesophagitis",
                "organSystem": "Gastrointestinal disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Malaise",
                "organSystem": "General disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Hepatic Function Abnormal",
                "organSystem": "Hepatobiliary disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Bronchitis",
                "organSystem": "Infections and infestations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Cystitis",
                "organSystem": "Infections and infestations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 3,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Influenza",
                "organSystem": "Infections and infestations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Contusion",
                "organSystem": "Injury, poisoning and procedural complications",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Fall",
                "organSystem": "Injury, poisoning and procedural complications",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Thermal Burn",
                "organSystem": "Injury, poisoning and procedural complications",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Alanine Aminotransferase Increased",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Blood Triglycerides Increased",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Eosinophil Count Increased",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Gamma-glutamyltransferase Increased",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 1,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "White Blood Cell Count Increased",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 1,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 2,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Blood Urine Present",
                "organSystem": "Investigations",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Myalgia",
                "organSystem": "Musculoskeletal and connective tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Musculoskeletal Pain",
                "organSystem": "Musculoskeletal and connective tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Musculoskeletal Stiffness",
                "organSystem": "Musculoskeletal and connective tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Sciatica",
                "organSystem": "Nervous system disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 2,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 0,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 0,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Insomnia",
                "organSystem": "Psychiatric disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 1,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Dermatitis Contact",
                "organSystem": "Skin and subcutaneous tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Eczema",
                "organSystem": "Skin and subcutaneous tissue disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 1,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              },
              {
                "term": "Hypertension",
                "organSystem": "Vascular disorders",
                "sourceVocabulary": "MedDRA (13.0)",
                "stats": [
                  {
                    "groupId": "EG000",
                    "numAffected": 0,
                    "numAtRisk": 84
                  },
                  {
                    "groupId": "EG001",
                    "numAffected": 0,
                    "numAtRisk": 77
                  },
                  {
                    "groupId": "EG002",
                    "numAffected": 2,
                    "numAtRisk": 81
                  },
                  {
                    "groupId": "EG003",
                    "numAffected": 2,
                    "numAtRisk": 83
                  }
                ]
              }
            ]
          },
          "moreInfoModule": {
            "certainAgreement": {
              "piSponsorEmployee": false,
              "restrictiveAgreement": false
            },
            "pointOfContact": {
              "title": "Atsushi Kamijo, Study Director",
              "organization": "Eisai Co., Ltd.",
              "email": "a-kamijo@hhc.eisai.co.jp",
              "phone": "+81-3-3817-5245"
            }
          }
        },
        "derivedSection": {
          "miscInfoModule": {
            "versionHolder": "2024-12-20"
          },
          "conditionBrowseModule": {
            "meshes": [
              {
                "id": "D007319",
                "term": "Sleep Initiation and Maintenance Disorders"
              }
            ],
            "ancestors": [
              {
                "id": "D020919",
                "term": "Sleep Disorders, Intrinsic"
              },
              {
                "id": "D020920",
                "term": "Dyssomnias"
              },
              {
                "id": "D012893",
                "term": "Sleep Wake Disorders"
              },
              {
                "id": "D009422",
                "term": "Nervous System Diseases"
              },
              {
                "id": "D001523",
                "term": "Mental Disorders"
              }
            ],
            "browseLeaves": [
              {
                "id": "M10356",
                "name": "Sleep Initiation and Maintenance Disorders",
                "asFound": "Insomnia",
                "relevance": "HIGH"
              },
              {
                "id": "M22242",
                "name": "Parasomnias",
                "relevance": "LOW"
              },
              {
                "id": "M22654",
                "name": "Sleep Disorders, Intrinsic",
                "relevance": "LOW"
              },
              {
                "id": "M22655",
                "name": "Dyssomnias",
                "relevance": "LOW"
              },
              {
                "id": "M15696",
                "name": "Sleep Wake Disorders",
                "relevance": "LOW"
              },
              {
                "id": "M14473",
                "name": "Psychotic Disorders",
                "relevance": "LOW"
              },
              {
                "id": "M4815",
                "name": "Mental Disorders",
                "relevance": "LOW"
              }
            ],
            "browseBranches": [
              {
                "abbrev": "BC10",
                "name": "Nervous System Diseases"
              },
              {
                "abbrev": "BXM",
                "name": "Behaviors and Mental Disorders"
              },
              {
                "abbrev": "All",
                "name": "All Conditions"
              },
              {
                "abbrev": "BC23",
                "name": "Symptoms and General Pathology"
              }
            ]
          },
          "interventionBrowseModule": {
            "meshes": [
              {
                "id": "D000069582",
                "term": "Eszopiclone"
              }
            ],
            "ancestors": [
              {
                "id": "D006993",
                "term": "Hypnotics and Sedatives"
              },
              {
                "id": "D002492",
                "term": "Central Nervous System Depressants"
              },
              {
                "id": "D045505",
                "term": "Physiological Effects of Drugs"
              }
            ],
            "browseLeaves": [
              {
                "id": "M4854",
                "name": "Benzocaine",
                "relevance": "LOW"
              },
              {
                "id": "M475",
                "name": "Eszopiclone",
                "asFound": "Atomoxetine",
                "relevance": "HIGH"
              },
              {
                "id": "M10043",
                "name": "Hypnotics and Sedatives",
                "relevance": "LOW"
              },
              {
                "id": "T433",
                "name": "Tannic Acid",
                "relevance": "LOW"
              }
            ],
            "browseBranches": [
              {
                "abbrev": "CNSDep",
                "name": "Central Nervous System Depressants"
              },
              {
                "abbrev": "All",
                "name": "All Drugs and Chemicals"
              },
              {
                "abbrev": "Ot",
                "name": "Other Dietary Supplements"
              }
            ]
          }
        },
        "hasResults": true
      }
    ]
  }